Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC)

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 3, 2004, Pages 395-401

  Popov, Ivan P ^a,b   Jelic, S B ^a   Matijasevic, M M ^a   Grbic, B ^a   Babic, D R ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Colorectal cancer; CPT 11; Infusional 5 fluorouracil; Oxaliplatin; Sequential chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 8544229102     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Moertel C., Fleming T., Macdonald J., et al.: Levamisole and fluorouracil for adjuvant therapy of resected colorectal carcinoma. N. Engl. J. Med. 322:352-359, 1990.
2. de Gramont A., Bosset J.F., Milan C., et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J. Clin. Oncol. 15:808-815, 1997.
3. Diaz-Rubio E. and Loboff B.: Management of advanced colorectal cancer. 14th ICACT. Paris-France 88-98, 2003.
4. Shimada Y., Rougier P., Pitot H.: Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur. J. Cancer 32A:S13-S17, 1996.
5. Becouarn Y., Ychou M., Ducreux M. et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol. 16:2739-2744, 1998.
6. Cunningham D., Zalcberg J., Rath U. et al.: Final results of a randomized trial comparing tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" colorectal cancer study group. Ann. Oncol. 7:981-985, 1996.
7. Cunningham D., James R.: Integrating the oral fluoropyridines into the management of advanced colorectal cancer. Eur. J. Cancer 37:826-834, 2001.
8. Therasse P., Arbuck S.G., Eisenhauer E.A. et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92(3): 205-216, 2000.
9. Meta-analysis group in cancer: Efficacy of intravenous continous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16: 301-308, 1998.
10. Meta-analysis group in cancer: Toxicity of fluorouracil on patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J. Clin. Oncol. 16:3537-3541, 1998.
11. Goldberg R.M., Morton R.F., Sargent D.J., et al.: N9741: Oxaliplatin or CPT-11 + 5-Fluorouracil/leucovorin or oxaliplatin+CPT-11 in advanced colorectal cancer: Initial toxicity and response data from a GI Intergroup study. Proc. Am. Soc. Clin. Oncol. 21:511, 2002.
12. Moertel C.G., Schutt A.J., Hahn R.G., Reitemeier R.J.: Effect of patients selection on results on phase II chemotherapy trials in gastrointestinal cancer. Cancer Chemother. Rep. 58: 257-259, 1974.
13. Piedbois P., Buyse M.: "What can we learn from meta-analysis of trials testing modulation of 5-fluorouracil by leucovorin?" Ann. Oncol. 4: S15-S19, 1993.
14. Cunningham D., Pyrhonen S., James R.D. et al.: Randomized trial of irinotecan plus supportive care vs supportive care alone with fluorouracile failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998.
15. Rougier P., Van Custem E., Bajetta E. et al.: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998.
16. Saltz L., Cox J., Blanke C. et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:905-914, 2000.
17. Douillard J.Y., Cunningham D.R. et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as a first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041-1047, 2000.
18. de Gramont A., Figer A., Seymour M. et al.: Leucovorin and fluorouracil with or without oxaliplatin as a first line treatment in advanced colorectal cancer. J. Clin. Oncol. 18: 2938-2947, 2000.
19. Giachetti S., Perpoint B., Zidani R. et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:136-147, 2000.
20. Tournigand C., Louvet C., Quinaux E. et al.: FOLFIR followed FOLFOX versus FOLFOX followed FOLFIR in metastatic colorectal cancer: Final result of a phase III study. Proc. Am. Soc. Clin. Oncol. 20: 494, 2001.